Role and Limits of COVID-19 Vaccines in the Delicate Transition from Pandemic Mitigation to Endemic Control

Role and Limits of COVID-19 Vaccines in the Delicate Transition from Pandemic Mitigation to Endemic Control

The recent surge of COVID-19 related to the Omicron variant emergence has thrown a harsh light upon epidemic control in the near future. This should lead the scientific and medical community to question the long-term vaccine strategy for SARS-CoV-2 control. We provide here a critical point of view r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccines (Basel) 2022-09, Vol.10 (9), p.1555
Hauptverfasser: Mura, Marie, Simon, Fabrice, Pommier de Santi, Vincent, Tangy, Frédéric, Tournier, Jean-Nicolas
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies
Control
Coronaviruses
COVID-19
COVID-19 vaccines
Critical point
Delta
Disease control
Disease transmission
Epidemics
Epidemiology
France
Immunology
Influenza
Interuniversity cooperation
Lymphocytes
mRNA vaccines
Omicron
Pandemics
Pharmaceutical industry
Review
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Strategy
vaccine
Vaccine development
Vaccines
variant
Viral diseases
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The recent surge of COVID-19 related to the Omicron variant emergence has thrown a harsh light upon epidemic control in the near future. This should lead the scientific and medical community to question the long-term vaccine strategy for SARS-CoV-2 control. We provide here a critical point of view regarding the virological evolution, epidemiological aspects, and immunological drivers for COVID-19 control, including a vaccination strategy. Overall, we need more innovations in vaccine development to reduce the COVID-19 burden long term. The most adequate answer might be better cooperation between universities, biotech and pharmaceutical companies
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10091555